CA2835284C - Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients - Google Patents
Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients Download PDFInfo
- Publication number
- CA2835284C CA2835284C CA2835284A CA2835284A CA2835284C CA 2835284 C CA2835284 C CA 2835284C CA 2835284 A CA2835284 A CA 2835284A CA 2835284 A CA2835284 A CA 2835284A CA 2835284 C CA2835284 C CA 2835284C
- Authority
- CA
- Canada
- Prior art keywords
- her2
- cutoff
- subject
- amount
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161488028P | 2011-05-19 | 2011-05-19 | |
| US61/488,028 | 2011-05-19 | ||
| PCT/US2012/038867 WO2012159115A1 (en) | 2011-05-19 | 2012-05-21 | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2835284A1 CA2835284A1 (en) | 2012-11-22 |
| CA2835284C true CA2835284C (en) | 2020-08-25 |
Family
ID=47175183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2835284A Active CA2835284C (en) | 2011-05-19 | 2012-05-21 | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20120295259A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3124975B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6468838B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2835284C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2615265T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG194609A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012159115A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11401344B2 (en) | 2008-12-01 | 2022-08-02 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
| US20120295259A1 (en) | 2011-05-19 | 2012-11-22 | Laboratory Corporation Of America Holdings | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients |
| US10451614B2 (en) | 2016-03-15 | 2019-10-22 | Laboratory Corporation Of America Holdings | Methods of assessing protein interactions between cells |
| EP3615067A1 (en) * | 2017-04-28 | 2020-03-04 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4318846A (en) | 1979-09-07 | 1982-03-09 | Syva Company | Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| JP2681061B2 (ja) | 1988-06-08 | 1997-11-19 | ロンドン・ダイアグノスティック・インコーポレーテッド | 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ |
| US4997928A (en) | 1988-09-15 | 1991-03-05 | E. I. Du Pont De Nemours And Company | Fluorescent reagents for the preparation of 5'-tagged oligonucleotides |
| US5654442A (en) | 1989-11-14 | 1997-08-05 | The Perkin-Elmer Corporation | 4,7-dichlorofluorescein dyes as molecular probes |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| ATE146508T1 (de) | 1990-11-02 | 1997-01-15 | Zeneca Ltd | Polysubstituierte phthalocyanine |
| JP2758730B2 (ja) | 1991-04-25 | 1998-05-28 | 三菱電機株式会社 | 放電励起パルスレーザ発振装置 |
| US6251581B1 (en) | 1991-05-22 | 2001-06-26 | Dade Behring Marburg Gmbh | Assay method utilizing induced luminescence |
| US5578498A (en) | 1991-05-22 | 1996-11-26 | Behringwerke Ag | Metal chelate containing compositions for use in chemiluminescent assays |
| US5340716A (en) | 1991-06-20 | 1994-08-23 | Snytex (U.S.A.) Inc. | Assay method utilizing photoactivated chemiluminescent label |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| WO1993021230A1 (en) | 1992-04-10 | 1993-10-28 | Dana-Farber Cancer Institute, Inc. | Activation-state-specific phosphoprotein immunodetection |
| JP3464798B2 (ja) | 1992-07-31 | 2003-11-10 | デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 光活性化化学発光基質 |
| US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| US5986076A (en) | 1994-05-11 | 1999-11-16 | Trustees Of Boston University | Photocleavable agents and conjugates for the detection and isolation of biomolecules |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US5945526A (en) | 1996-05-03 | 1999-08-31 | Perkin-Elmer Corporation | Energy transfer dyes with enhanced fluorescence |
| US5763602A (en) | 1996-10-01 | 1998-06-09 | Li; Ying-Syi | Methods of syntheses of phthalocyanine compounds |
| US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
| US6001673A (en) | 1999-02-11 | 1999-12-14 | Ericsson Inc. | Methods for packaging integrated circuit devices including cavities adjacent active regions |
| US6627400B1 (en) | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
| US6673550B2 (en) | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
| US20030235832A1 (en) | 2000-06-21 | 2003-12-25 | Ahmed Chenna | Multiplexed analysis by chromatographic separation of molecular tags |
| US6191278B1 (en) | 1999-11-03 | 2001-02-20 | Pe Corporation | Water-soluble rhodamine dyes and conjugates thereof |
| US6372907B1 (en) | 1999-11-03 | 2002-04-16 | Apptera Corporation | Water-soluble rhodamine dye peptide conjugates |
| US6346384B1 (en) | 2000-03-27 | 2002-02-12 | Dade Behring Inc. | Real-time monitoring of PCR using LOCI |
| US20030170734A1 (en) | 2000-04-28 | 2003-09-11 | Stephen Williams | Multiplexed assays using electrophoretically separated molecular tags |
| EP1305632B1 (en) | 2000-05-04 | 2011-07-27 | Siemens Healthcare Diagnostics Products GmbH | Methods for detection of multiple analytes |
| WO2003051669A1 (en) | 2001-12-18 | 2003-06-26 | Aclara Biosciences, Inc. | Photoactivation device and method |
| EP1478765A4 (en) | 2002-03-05 | 2006-12-06 | Aclara Biosciences Inc | MULTIPLEX ANALYSIS USING MEMBRANE-FIXED SENSITIZERS |
| US7402397B2 (en) | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| ATE442589T1 (de) | 2002-07-25 | 2009-09-15 | Aclara Biosciences Inc | Nachweis der rezeptoroligomerisierung |
| US7402398B2 (en) | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| WO2005011607A2 (en) * | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
| WO2005037071A2 (en) | 2003-10-14 | 2005-04-28 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
| WO2006086730A2 (en) * | 2005-02-09 | 2006-08-17 | Genentech, Inc. | Inhibiting her2 shedding with matrix metalloprotease antagonists |
| WO2009086197A1 (en) | 2007-12-20 | 2009-07-09 | Monogram Biosciences, Inc. | Her-2 diagnostic methods |
| EP2438442B1 (en) * | 2008-12-01 | 2017-08-09 | Laboratory Corporation of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| US20120295259A1 (en) | 2011-05-19 | 2012-11-22 | Laboratory Corporation Of America Holdings | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients |
| US20100233732A1 (en) | 2009-01-15 | 2010-09-16 | Laboratory Corporation Of America Holdings | Methods of Determining Patient Response By Measurement of HER-2 Expression |
| BRPI1007321A2 (en) * | 2009-01-15 | 2018-07-10 | Laboratory Corporation Of America Holdings | methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody. |
| NZ596468A (en) * | 2009-05-14 | 2013-11-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| ES2363669B1 (es) * | 2009-06-10 | 2012-08-09 | Fundacio Privada Institut D'investigacio Biomedica De Bellvitge (Idibell) | Metodo para determinar el riesgo de desarrollar metastasis cerebral y un kit para llevar a cabo dicho procedimiento |
| JP5795311B2 (ja) * | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
-
2012
- 2012-05-21 US US13/476,735 patent/US20120295259A1/en not_active Abandoned
- 2012-05-21 CA CA2835284A patent/CA2835284C/en active Active
- 2012-05-21 EP EP16189315.1A patent/EP3124975B1/en active Active
- 2012-05-21 EP EP12785543.5A patent/EP2710379B1/en active Active
- 2012-05-21 JP JP2014511615A patent/JP6468838B2/ja active Active
- 2012-05-21 ES ES12785543.5T patent/ES2615265T3/es active Active
- 2012-05-21 WO PCT/US2012/038867 patent/WO2012159115A1/en not_active Ceased
- 2012-05-21 SG SG2013078977A patent/SG194609A1/en unknown
- 2012-05-21 ES ES16189315T patent/ES2701929T3/es active Active
-
2017
- 2017-05-09 JP JP2017093074A patent/JP6626037B2/ja active Active
-
2018
- 2018-10-22 US US16/166,816 patent/US11579148B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014515477A (ja) | 2014-06-30 |
| JP2017138334A (ja) | 2017-08-10 |
| JP6626037B2 (ja) | 2019-12-25 |
| ES2615265T3 (es) | 2017-06-06 |
| JP6468838B2 (ja) | 2019-02-13 |
| WO2012159115A1 (en) | 2012-11-22 |
| EP3124975B1 (en) | 2018-12-05 |
| US20190257836A1 (en) | 2019-08-22 |
| CA2835284A1 (en) | 2012-11-22 |
| EP2710379A4 (en) | 2015-04-08 |
| EP2710379A1 (en) | 2014-03-26 |
| US11579148B2 (en) | 2023-02-14 |
| US20120295259A1 (en) | 2012-11-22 |
| SG194609A1 (en) | 2013-12-30 |
| EP2710379B1 (en) | 2016-12-14 |
| ES2701929T3 (es) | 2019-02-26 |
| EP3124975A1 (en) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2711843C (en) | Her-2 diagnostic methods | |
| EP2387717B1 (en) | Methods of determining patient response by measurement of her-2 expression | |
| JP6402173B2 (ja) | Her3の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法 | |
| US11579148B2 (en) | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients | |
| US20130216523A1 (en) | Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression | |
| CN108780089B (zh) | 评估细胞间的蛋白质相互作用的方法 | |
| US20260125490A1 (en) | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170424 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250516 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250516 |